

Press Release May 25, 2016

BioMedPartners strengthens management team

Basel, Switzerland – BioMedPartners, one of Europe’s leading healthcare venture capital firms, has strengthened its management team with the addition of Dr. Andreas Wallnöfer.

Dr. Andreas Wallnöfer will join BioMedPartners team in Basel, Switzerland as a new Partner on September 1, 2016. Dr. Wallnöfer is a senior executive with more than 20 years experience in the pharmaceutical industry, including 12 years as a member of the F. Hoffmann-La Roche Pharma R&D Leadership and Portfolio Committee. He led the Roche Pharma Cardiovascular & Metabolism Disease Area and left Roche in 2015 after the company strategically decided to exit these research areas. At Roche he was involved in several successful product development programs and thus will strengthen BioMed’s expertise in Pharma from discovery to regulatory filing submissions. Dr. Wallnöfer had a key role in the integration of the Roche and Genentech Development organizations and subsequently led Early Development and Portfolio Management at Roche. Furthermore, he and his groups were involved in the due diligence evaluations of in-licensing projects and product acquisitions. As Head of Clinical Research & Exploratory Development Dr. Wallnöfer was a key driver for the implementation of the Roche Personalized Health Care strategy, and recently advised the University of Basel in the development of such a strategy in the academic setting, in collaboration with ETH and the University of Zürich. Dr. Wallnöfer obtained his PhD in pharmacology from the University of Basel and trained as a fellow in Clinical Pharmacology at the University of Leiden, the Netherlands. In addition, he holds a Master of Technology Enterprise and an Executive MBA from IMD Lausanne.

Dr. Markus Hosang and Thomas Möller, General Partners at BioMedPartners, commented: “We are very pleased to welcome Dr. Andreas Wallnöfer as a new member of our team. His strong scientific and industry background as well as his long-term experience in pharma research and development are highly beneficial assets that will not only help us provide valuable support to our existing portfolio companies, but also strengthen BioMedPartners’ role as an active lead investor in the biopharmaceutical space in the Alpine Rim region in the future.”

About BioMedPartners

BioMedPartners is a leading independent European venture capital firm, providing private equity and mezzanine financing to early- to mid-stage life sciences companies. Since 2003, BioMedPartners has invested in more than 50 highly innovative companies, of which 17 have already either successfully been acquired by leading biopharma players (e.g. ESBATech AG, Glycart Biotechnology AG, Okairos AG and SuppreMol GmbH) or have completed an IPO (Affimed AG, Curetis AG, Santhera Pharmaceuticals AG). With more than CHF 250 million in capital under management and a strong team of experienced industry experts as well as an extensive scientific network, BioMedPartners has established itself as one of the leading early-stage life sciences investors in Europe.

For further information, please contact:

Dr. Markus Hosang
T: +41 61 270 35 63
hosang@biomedvc.com

Thomas Möller
T: +41 61 270 35 67
moeller@biomedvc.com